

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES



Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
 - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
 - FADED TEXT
 - ILLEGIBLE TEXT
 - SKEWED/SLANTED IMAGES
 - COLORED PHOTOS
 - BLACK OR VERY BLACK AND WHITE DARK PHOTOS
 - GRAY SCALE DOCUMENTS
-

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



chain nodes :

1 2 3 4 5 6 7 8 9 10 12 13 16

chain bonds :

1-2 2-3 3-4 4-5 4-6 6-7 6-13 6-16 7-8 8-9 8-10 8-12

exact/norm bonds :

2-3 3-4 4-5 6-13 6-16 7-8 8-9 8-10 8-12

exact bonds :

1-2 4-6 6-7

G1: Cy, Ak

G2: O, N, X

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS
9:CLASS 10:CLASS 12:CLASS 13:CLASS 16:CLASS

FILE 'HOME' ENTERED AT 08:37:27 ON 09 MAY 2001

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading c:\stnexp4\queries\09530965.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> s l1

SAMPLE SEARCH INITIATED 08:38:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.17

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 80 TO 560

PROJECTED ANSWERS: 6 TO 266


L3 6 SEA SSS SAM L1

=> d scan

L3 6 ANSWERS REGISTRY COPYRIGHT 2001 ACS


IN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N,2-dihydroxy-2-
[[(2-pyridinylmethyl)thio]methyl]- (9CI)

MF C22 H21 Cl N2 O5 S2




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 6 ANSWERS REGISTRY COPYRIGHT 2001 ACS
 IN Benzamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]-4-propyl- (9CI)
 MF C20 H24 N2 O6 S



L3 6 ANSWERS REGISTRY COPYRIGHT 2001 ACS
 IN Benzamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]-3-nitro- (9CI)
 MF C17 H17 N3 O8 S



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading c:\stnexp4\queries\09530965.str

L4 STRUCTURE UPLOADED


=> que L4

L5 QUE L4

=> d l4

L4 HAS NO ANSWERS

L4 STR



G1 Cy,Ak
G2 O,N,X

Structure attributes must be viewed using STN Express query preparation.

=> s 14

SAMPLE SEARCH INITIATED 08:41:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 123 TO ITERATE

100.0% PROCESSED 123 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.04

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1795 TO 3125
PROJECTED ANSWERS: 6 TO 265

L6 6 SEA SSS SAM L4

=> s 14 ful

FULL SEARCH INITIATED 08:41:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2635 TO ITERATE

100.0% PROCESSED 2635 ITERATIONS 116 ANSWERS
SEARCH TIME: 00.00.05

L7 116 SEA SSS FUL L4

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	135.42	135.57

FILE 'CAPLUS' ENTERED AT 08:42:04 ON 09 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 9 May 2001 VOL 134 ISS 20
FILE LAST UPDATED: 8 May 2001 (20010508/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> s 17


L8 5 L7

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y


18 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS
 X
 ACCESSION NUMBER: 2001:63816 CAPLUS
 DOCUMENT NUMBER: 134:136687
 TITLE: Method of changing conformation of a matrix metalloproteinase
 INVENTOR(S): Stallings, William C.; Shieh, Huey S.; Howard, Susan C.; De Crescenzo, Gary A.; McDonald, Joseph J.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005389	A2	20010125	WO 2000-US16323	20000712
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-144133	P 19990716
OTHER SOURCE(S):		MARPAT 134:136687		
GI				



AB The present invention provides a matrix metalloproteinase inhibiting compd. having structure or a salt, an enantiomer, a diastereomer, a racemate, or a tautomer thereof. The present invention provides a method of changing the conformation of a matrix metalloproteinase, a method of inhibiting a matrix metalloproteinase, and a method of treating osteoarthritis. An example was given for the prepn. of I and another example given for cloning, expression and purifn. of the catalytic domain of MMP-8.
 IT **213183-78-9**
 RL: PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (changing conformation of a matrix metalloproteinase and enzyme inhibitors)
 RN 213183-78-9 CAPLUS

CN Propanamide, N,2-dihydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]- (9CI)
(CA INDEX NAME)



18 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 2000:842109 CAPLUS
 DOCUMENT NUMBER: 134:29702
 TITLE: Preparation of .alpha.-amino-.beta.-sulfonyl
 hydroxamic acid compounds as matrix metalloprotease
 inhibitors
 INVENTOR(S): Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis
 J.;
 De Crescenzo, Gary A.; Freskos, John N.; Getman,
 Daniel P.; Heintz, Robert M.; Hockerman, Susan L.;
 Li,
 Hui; Mischke, Brent V.; Villamil, Clara I.
 PATENT ASSIGNEE(S): G.D. Searle & Co., USA
 SOURCE: PCT Int. Appl., 202 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000071514	A1	20001130	WO 2000-US9807	20000517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-134996 P 19990520

OTHER SOURCE(S): MARPAT 134:29702

AB Comps. R5COCR2(NR3R4)CH2SO2R1 [R1 is an optionally substituted 5- or
 6-membered carbocyclyl, heterocyclyl, aryl or heteroaryl radical such
 that

its size is defined by certain parameters; R2 = H, hydrocarbyl,
 hydroxyhydrocarbyl, hydrocarbyloxy, halohydrocarbyl,
 hydrocarbyloxymethyl,
 aryl, arylhydrocarbyl, aminomethyl, hydrocarbylaminomethyl,
 morpholinomethyl, (thio)pyrrolidinomethyl; R3, R4 = H, acyl group,
 aralkyl, carboxyalkyl, heteroaralkylthio, or a sulfoxide or sulfone of

the
 thio substituents, alkyl- or arylsulfonyl, aminocarbonylalkyl; R5 is
 -O-R21, -NR13-O-R22 or -NR13-O-R14, where R21 is H, alkyl, aryl,
 arylalkyl, a pharmaceutically acceptable cation, R22 is a selectively
 removable protecting group, R13 is H, alkyl, benzyl, R14 is H, a
 pharmaceutically acceptable cation, or a (thio)carbonyl group (with
 provisos)] were prepd. for inhibition of matrix metalloproteinase (MMP)
 activity, particularly the activity of one or more of MMP-2, MMP-9, or
 MMP-13, while generally exhibiting little activity against MMP-1. A
 contemplated compd. also exhibits little inhibition of the prodn. of TNF.
 Thus, N-hydroxy-3-[(4-methoxyphenyl)sulfonyl]-2-
 [(phenylcarbonyl)amino]propanamide was prepd. and showed IC50 = 2000 and
 25.0 nM for inhibition of MMP-1 and MMP-13, resp. and 3.72% inhibition of
 TNF at 10 .mu.M.

IT 310464-19-8P 310464-20-1P 310464-22-3P


310464-24-5P 310464-25-6P 310464-26-7P
 310464-27-8P 310464-28-9P 310464-30-3P
 310464-31-4P 310464-32-5P 310464-33-6P
 310464-34-7P 310464-53-0P 310464-54-1P
 310464-62-1P 310464-65-4P 310464-68-7P
 310464-69-8P 310464-70-1P 310464-72-3P
 310464-75-6P 310464-76-7P 310464-77-8P
 310464-78-9P 310464-79-0P 310464-80-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminosulfonyl hydroxamic acid compds. as matrix metalloprotease inhibitors)


RN 310464-19-8 CAPLUS

CN Propanamide, 2-amino-N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 310464-20-1 CAPLUS

CN Propanamide, 2-(acetylamino)-N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 310464-22-3 CAPLUS

CN 1-Pyrrolidineacetamide, N-[2-(hydroxyamino)-1-methyl-2-oxo-1-[(4-phenoxyphenyl)sulfonyl]methyl]ethyl]- (9CI) (CA INDEX NAME)




RN 310464-24-5 CAPLUS

CN Propanamide, 2-(dimethylamino)-N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 310464-25-6 CAPLUS

CN Propanamide, N-hydroxy-2-methyl-2-[(2-naphthalenylmethyl)amino]-3-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 310464-26-7 CAPLUS


CN Propanamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 310464-27-8 CAPLUS
 CN Propanamide, N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-2-[(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)




RN 310464-28-9 CAPLUS
 CN Benzeneacetamide, .alpha.-amino-N-hydroxy-.alpha.-[[4-phenoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 310464-30-3 CAPLUS
 CN Propanamide, N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 310464-31-4 CAPLUS
 CN Propanamide, 2-(acetamino)-N-hydroxy-2-methyl-3-[[4-(phenylthio)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 310464-32-5 CAPLUS
 CN Benzamide, N-[4-[[2-amino-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 310464-33-6 CAPLUS

CN Propanamide, 2-amino-N-hydroxy-2-methyl-3-[[4-(phenylthio)phenyl]sulfonyl]-
(9CI) (CA INDEX NAME)



RN 310464-34-7 CAPLUS

CN Carbamic acid, [1-[[[4-(benzoylamino)phenyl]sulfonyl]methyl]-2-(hydroxyamino)-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 310464-53-0 CAPLUS

CN Propanamide, 2-amino-N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 310464-19-8


CMF C16 H18 N2 O5 S




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 310464-54-1 CAPLUS
 CN Propanamide, 2-amino-N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 310464-62-1 CAPLUS
 CN 1-Pyrrolidineacetamide, N-[2-(hydroxyamino)-1-methyl-2-oxo-1-[(4-phenoxyphenyl)sulfonyl]methyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 310464-65-4 CAPLUS
 CN Propanamide, 2-(dimethylamino)-N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 310464-68-7 CAPLUS
 CN Propanamide, 2-(ethylamino)-N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 310464-69-8 CAPLUS
 CN Propanamide, N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-2-[(phenylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 310464-70-1 CAPLUS
 CN Propanamide, 2-amino-N-hydroxy-2-methyl-3-[[4-(phenylthio)phenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 310464-72-3 CAPLUS
 CN Benzamide, N-[4-[[2-amino-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 310464-75-6 CAPLUS
 CN Benzeneacetamide, .alpha.-(benzoylamino)-N-hydroxy-.alpha.-[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 310464-76-7 CAPLUS
 CN Propanamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 310464-77-8 CAPLUS
 CN Propanamide, N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-2-[(2-phenylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 310464-78-9 CAPLUS


CN Propanamide, N-hydroxy-2-methyl-2-[(2-naphthalenylmethyl)amino]-3-[(4-phenoxyphenyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 310464-79-0 CAPLUS


CN Propanamide, N-hydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-2-(2-propynylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 310464-80-3 CAPLUS

CN Benzeneacetamide, .alpha.-amino-N-hydroxy-.alpha.-[[(4-phenoxyphenyl)sulfonyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

REFERENCE COUNT:

8


REFERENCE(S):

- (1) Dua, R; JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
1993, V115(4), P1264 CAPLUS
 - (3) Hornback, W; US 5480887 A 1996 CAPLUS
 - (5) La Roche, H; EP 0780386 A 1997 CAPLUS
 - (6) Monsanto; WO 9803164 A 1998 CAPLUS
 - (7) Ono Pharmaceutical; WO 9749679 A 1997 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~18~~ ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1999:354468 CAPLUS
 DOCUMENT NUMBER: 131:18833
 TITLE: Preparation of .alpha.-hydroxy, -amino, and halo derivatives of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors
 INVENTOR(S): Warpehoski, Martha A.; Mitchell, Mark Allen; Harper, Donald E.; Maggiora, Linda Louise
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

applicant

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9926909	A2	19990603	WO 1998-IB2154	19981118
WO 9926909	A3	19990826		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9925405	A1	19990615	AU 1999-25405	19981118
EP 1037868	A2	20000927	EP 1998-966869	19981118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9814699	A	20001003	BR 1998-14699	19981118
NO 2000002505	A	20000630	NO 2000-2505	20000515
PRIORITY APPLN. INFO.:			US 1997-72655	P 19971121
			WO 1998-IB2154	W 19981118
OTHER SOURCE(S):		MARPAT 131:18833		
GI				



AB The title compds. [I; R1 = C4-12 alkyl, C4-12 alkenyl, C4-12 alkynyl, etc.; R2 = C1-12 alkyl, C4-12 alkenyl, C4-12 alkynyl, etc.; Y = OH, NR9R10, F; R9, R10 = H, COR3, CO2R3, etc.; R3 = H, cycloalkyl, alkyl, etc.], inhibitors of matrix metalloproteinases which are useful in treating osteoarthritis, rheumatoid arthritis, septic arthritis, osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation, or asthma, were prepd. E.g., a 7-step synthesis of I [R1 = 4-PhC6H4; R2 = 4-MeOC6H4SO2CH2; Y = OH] which showed Ki of 0.074 .mu.M and 0.0019 .mu.M against stromelysin and gelatinase, resp.


IT 226419-27-8P 226419-28-9P 226419-29-0P
 226419-30-3P 226419-31-4P 226419-32-5P
 226419-33-6P 226419-34-7P 226419-35-8P
 226419-36-9P 226419-37-0P 226419-38-1P
 226419-39-2P 226419-40-5P 226419-41-6P
 226419-42-7P 226419-43-8P 226419-44-9P
 226419-45-0P 226419-46-1P 226419-47-2P
 226419-48-3P 226419-49-4P 226419-50-7P
 226419-51-8P 226419-52-9P 226419-53-0P
 226419-54-1P 226419-55-2P 226419-56-3P
 226419-57-4P 226419-58-5P 226419-59-6P
 226419-60-9P 226419-61-0P 226419-62-1P
 226419-63-2P 226419-64-3P 226419-65-4P
 226419-66-5P 226419-67-6P 226419-68-7P
 226419-69-8P 226419-70-1P 226419-71-2P
 226419-73-4P 226419-75-6P 226419-77-8P
 226419-79-0P 226419-81-4P 226419-83-6P
 226419-84-7P 226419-85-8P 226419-86-9P
 226419-87-0P 226419-88-1P 226419-89-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of .alpha.-hydroxy, -amino, and halo derivs. of .beta.-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors)

RN 226419-27-8 CAPLUS

CN Propanamide, 3-([1,1'-biphenyl]-4-ylsulfonyl)-N,2-dihydroxy-2-[[4-methoxyphenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




$R^1C(=O)NH-OH$

514/575
 962/621
 hydroxamic acid
 $R^1C(=O)NR^2$

RN 226419-28-9 CAPLUS


CN Propanamide, 3-[(4-fluorophenyl)sulfonyl]-N,2-dihydroxy-2-[[4-methoxyphenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)



4-OMe
 R¹C-OCH₃
 imidate and
 on


RN 226419-29-0 CAPLUS

CN Propanamide, 3-[(4-butylphenyl)sulfonyl]-N,2-dihydroxy-2-[[4-methoxyphenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 226419-30-3 CAPLUS

CN Propanamide, N,2-dihydroxy-3-[(4-methoxyphenyl)sulfonyl]-2-[[4-methoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 226419-31-4 CAPLUS

CN Benzamide, N-[2-hydroxy-3-(hydroxyamino)-2-[[4-methoxyphenyl)sulfonyl]methyl]-3-oxopropyl]- (9CI) (CA INDEX NAME)




RN 226419-32-5 CAPLUS

CN Cyclopentanecarboxamide, N-[2-hydroxy-3-(hydroxyamino)-2-[[4-methoxyphenyl)sulfonyl]methyl]-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 226419-33-6 CAPLUS


CN Benzamide, N-[2-hydroxy-3-(hydroxyamino)-2-[[4-methoxyphenyl)sulfonyl]methyl]-3-oxopropyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 226419-34-7 CAPLUS

CN Propanamide, 3-([1,1'-biphenyl]-4-ylsulfonyl)-N,2-dihydroxy-2-[(4-methoxyphenyl)sulfonylmethyl]-, (+)-(9CI) (CA INDEX NAME)


Rotation (+).



RN 226419-35-8 CAPLUS


CN Propanamide, 3-([1,1'-biphenyl]-4-ylsulfonyl)-N,2-dihydroxy-2-[(4-methoxyphenyl)sulfonylmethyl]-, (-)-(9CI) (CA INDEX NAME)

Rotation (-).



RN 226419-36-9 CAPLUS

CN 1-Imidazolidinepropanamide, N,.alpha.-dihydroxy-.alpha.-[(4-methoxyphenyl)sulfonylmethyl]-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)




508 / 319.5
514 / 392

RN 226419-37-0 CAPLUS


CN 1-Imidazolidinepropanamide, N,.alpha.-dihydroxy-.alpha.-[(4-methoxyphenyl)sulfonyl]methyl]-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA

INDEX
NAME)




RN 226419-38-1 CAPLUS

CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl)sulfonyl]methyl]-N,.alpha.-dihydroxy-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 226419-39-2 CAPLUS

CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl) sulfonyl]methyl]-3-butyl-N,.alpha.-dihydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 226419-40-5 CAPLUS

CN 1-Imidazolidinepropanamide, .alpha.-[[(4-butoxyphenyl) sulfonyl]methyl]-N,.alpha.-dihydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI) (CA INDEX NAME)




RN 226419-41-6 CAPLUS

CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[(methylthio)methyl]- (9CI) (CA INDEX NAME)




RN 226419-42-7 CAPLUS

CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 226419-43-8 CAPLUS

CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[[(phenylmethyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 226419-44-9 CAPLUS

CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[(2-pyridinylthio)methyl]- (9CI) (CA INDEX NAME)



RN 226419-45-0 CAPLUS


CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]- (9CI) (CA INDEX NAME)



544/223
514/2+2

RN 226419-46-1 CAPLUS


CN Propanamide, 3-[(2-amino-5-thiazolyl)thio]-2-[[[(4-butoxyphenyl)sulfonyl]methyl]-N,2-dihydroxy- (9CI) (CA INDEX NAME)



548/185
514/370

RN 226419-47-2 CAPLUS


CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]- (9CI) (CA INDEX NAME)



548/129
514/361

RN 226419-48-3 CAPLUS


CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[(1-methyl-1H-imidazol-2-yl)thio]methyl]- (9CI) (CA INDEX NAME)



548/324.1
514/398

RN 226419-49-4 CAPLUS


CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[(1-methyl-1H-tetrazol-5-yl)thio]methyl]- (9CI) (CA INDEX NAME)



548/251
514/381

RN 226419-50-7 CAPLUS


CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[(tetrazolo[1,5-b]pyridazin-6-ylthio)methyl]- (9CI) (CA INDEX NAME)



544/236
514/248


RN 226419-51-8 CAPLUS

CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[(2-pyridinylmethyl)thio]methyl]- (9CI) (CA INDEX NAME)




546/334
514/357

RN 226419-52-9 CAPLUS
CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[[[(1-methyl-1H-imidazol-2-yl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)




548/338.1
514/399

RN 226419-53-0 CAPLUS
CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[[[(1-phenylmethyl)-1H-imidazol-2-yl]methyl]thio]methyl]- (9CI) (CA INDEX NAME)




RN 226419-54-1 CAPLUS
CN Propanamide, 3-[(4-butoxyphenyl)sulfonyl]-N,2-dihydroxy-2-[[[(5-methyl-3-isoxazolyl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)




548/272.1
514/378

RN 226419-55-2 CAPLUS
CN Butanamide, 2-[[[(4-butoxyphenyl)sulfonyl]methyl]-N,2-dihydroxy-4-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 226419-56-3 CAPLUS
 CN Pentonamide, 2-C-[[4-(4-butoxyphenyl)sulfonyl]methyl]-3,5-dideoxy-N-hydroxy-4-S-2-pyridinyl-4-thio- (9CI) (CA INDEX NAME)




RN 226419-57-4 CAPLUS
 CN 1-Imidazolidinepropanamide, .alpha.-[[4-(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl]-N,.alpha.-dihydroxy-3-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 226419-58-5 CAPLUS
CN 1-Imidazolidinepropanamide, 3-butyl-.alpha.-[[(4'-chloro[1,1'-biphenyl]-
4- yl)sulfonyl)methyl]-N,.alpha.-dihydroxy-2,5-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 226419-59-6 CAPLUS
CN 1-Imidazolidinepropanamide, .alpha.-[[(4'-chloro[1,1'-biphenyl]-4-
yl)sulfonyl)methyl]-N,.alpha.-dihydroxy-3,4,4-trimethyl-2,5-dioxo- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 226419-60-9 CAPLUS

CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N,2-dihydroxy-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 226419-61-0 CAPLUS

CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N,2-dihydroxy-2-[(phenylmethyl)thio]methyl]- (9CI) (CA INDEX NAME)




RN 226419-62-1 CAPLUS

CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N,2-dihydroxy-2-[[2-pyridinylmethyl]thio]methyl- (9CI) (CA INDEX NAME)



RN 226419-63-2 CAPLUS


CN Propanamide, 3-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-N,2-dihydroxy-2-[[[5-methyl-3-isoxazolyl)methyl]thio]methyl- (9CI) (CA INDEX NAME)




RN 226419-64-3 CAPLUS

CN Pentonamide, 2-C-[[4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]methyl-3,4,5-trideoxy-N-hydroxy-4-(3-methyl-2,5-dioxo-1-imidazolidinyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 226419-65-4 CAPLUS
 CN Pentonamide, 2-C-[[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl)methyl]-3,5-dideoxy-N-hydroxy-4-S-2-pyridinyl-4-thio- (9CI) (CA INDEX NAME)




RN 226419-66-5 CAPLUS
 CN 1-Imidazolidinepropanamide, N,.alpha.-dihydroxy-3-methyl-2,5-dioxo-.alpha.-
 [[(4-phenoxyphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 226419-67-6 CAPLUS

CN 1-Imidazolidinepropanamide, 3-butyl-N,.alpha.-dihydroxy-2,5-dioxo-
.alpha.-
[[(4-phenoxyphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 226419-68-7 CAPLUS

CN 1-Imidazolidinepropanamide, N,.alpha.-dihydroxy-3,4,4-trimethyl-2,5-
dioxo-
.alpha.-[[(4-phenoxyphenyl)sulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 226419-69-8 CAPLUS

CN 1-Imidazolidinepropanamide, N,.alpha.-dihydroxy-2,5-dioxo-.alpha.-[[(4-phenoxyphenyl)sulfonyl]methyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 226419-70-1 CAPLUS

CN Propanamide, N,2-dihydroxy-2-[[(4-phenoxyphenyl)sulfonyl]methyl]-3-(phenylthio)- (9CI) (CA INDEX NAME)




RN 226419-71-2 CAPLUS

CN Propanamide, N,2-dihydroxy-2-[[(4-phenoxyphenyl)sulfonyl]methyl]-3-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 226419-73-4 CAPLUS

CN Propanamide, N,2-dihydroxy-2-[[[(4-phenoxyphenyl)sulfonyl]methyl]-3-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 226419-75-6 CAPLUS

CN Propanamide, N,2-dihydroxy-2-[[[(1-methyl-1H-imidazol-2-yl)methyl]thio]methyl]-3-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 226419-77-8 CAPLUS

CN Pentonamide, 3,4,5-trideoxy-N-hydroxy-4-(3-methyl-2,5-dioxo-1-imidazolidinyl)-2-C-[[[(4-phenoxyphenyl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)



RN 226419-79-0 CAPLUS


CN Pentonamide, 3,5-dideoxy-N-hydroxy-4-S-(1-methyl-1H-imidazol-2-yl)-2-C-[[4-(4-phenoxyphenyl)sulfonyl]methyl]-4-thio- (9CI) (CA INDEX NAME)



RN 226419-81-4 CAPLUS

CN 1-Imidazolidinepropanamide, N,.alpha.-dihydroxy-3-methyl-2,5-dioxo-.alpha.-[[[4-(4-pyridinyl)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 226419-83-6 CAPLUS
CN 1-Imidazolidinepropanamide, 3-butyl-N,.alpha.-dihydroxy-2,5-dioxo-
.alpha.-
[[[4-(4-pyridinyl)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 226419-84-7 CAPLUS
CN 1-Imidazolidinepropanamide, N,.alpha.-dihydroxy-3,4,4-trimethyl-2,5-
dioxo-
.alpha.-[[[4-(4-pyridinyl)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 226419-85-8 CAPLUS
 CN Propanamide, N,2-dihydroxy-2-[(phenylthio)methyl]-3-[[4-(4-pyridinyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 226419-86-9 CAPLUS
 CN Propanamide, N,2-dihydroxy-2-[[(phenylmethyl)thio]methyl]-3-[[4-(4-pyridinyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 226419-87-0 CAPLUS


CN Pentonamide, 3,5-dideoxy-N-hydroxy-4-S-(phenylmethyl)-2-C-[[[4-(4-pyridinyl)phenyl]sulfonyl]methyl]-4-thio- (9CI) (CA INDEX NAME)



RN 226419-88-1 CAPLUS

CN 1-Imidazolidinepropanamide, N,.alpha.-dihydroxy-3,4,4-trimethyl-2,5-dioxo-.alpha.-[[[4-(4-pyridinyloxy)phenyl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 226419-89-2 CAPLUS

CN Propanamide, N,2-dihydroxy-2-[[(phenylmethyl)thio]methyl]-3-[[4-(4-pyridinyloxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:612095 CAPLUS

DOCUMENT NUMBER: 129:244921

TITLE: Preparation of aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds as matrix metalloprotease inhibitors

INVENTOR(S): Freskos, John N.; Boehm, Terri L.; Mischke, Brent V.; Heintz, Robert M.; McDonald, Joseph J.; Decrescenzo, Gary A.; Howard, Susan C.

PATENT ASSIGNEE(S): Monsanto Company, USA

SOURCE: PCT Int. Appl., 203 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9839326 105	A1	19980911	WO 1998-US4277	19980304
W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9864478	A1	19980922	AU 1998-64478	19980304
EP 984959	A1	20000315	EP 1998-910177	19980304
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
BR 9808150	A	20000328	BR 1998-8150	19980304
PRIORITY APPLN. INFO.:			US 1997-35182 P 19970304	
			WO 1998-US4277 W 19980304	
OTHER SOURCE(S):	MARPAT 129:244921			
AB	The title compds. HONHC(O)C(OH)(R2)CH2SO2R1 [I; R2 = H, C1-4 alkyl, C1-4 haloalkyl, etc.; R1 = 5-6 membered cycloalkyl, heterocyclyl, aryl, etc.] which inter alia inhibit matrix metalloprotease activity, were prepd. Thus, multi-step synthesis of I [R1 = 4-PhOC6H4; R2 = Me] which showed 51.9% inhibition of angiogenesis in the cornea of a mouse, was described.			
IT	213183-78-9P 213183-79-0P 213183-80-3P 213183-81-4P 213183-82-5P 213183-83-6P 213183-84-7P 213183-85-8P 213183-86-9P 213183-93-8P 213183-94-9P 213183-96-1P 213183-97-2P 213183-98-3P 213183-99-4P 213184-00-0P 213184-01-1P 213184-03-3P 213184-04-4P 213184-06-6P 213184-07-7P 213184-08-8P 213184-09-9P 213184-10-2P 213184-12-4P 213184-13-5P 213184-14-6P 213184-15-7P 213184-16-8P 213184-17-9P 213184-18-0P			
RL:	BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(prepn. of arom. sulfonyl alpha-hydroxy hydroxamic acid compds. as matrix metalloprotease inhibitors)			
RN	213183-78-9 CAPLUS			
CN	Propanamide, N,2-dihydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]- (9CI)			


(CA INDEX NAME)



RN 213183-79-0 CAPLUS

CN Propanamide, N,2-dihydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-, (2S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 213183-80-3 CAPLUS


CN Propanamide, N,2-dihydroxy-2-methyl-3-[(4-phenoxyphenyl)sulfonyl]-, (2R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 213183-81-4 CAPLUS

CN Propanamide, N,2-dihydroxy-2-(hydroxymethyl)-3-[(4-phenoxyphenyl)sulfonyl]-
(9CI) (CA INDEX NAME)



RN 213183-82-5 CAPLUS


CN 4-Morpholinepropanamide, N,.alpha.-dihydroxy-.alpha.-[[(4-phenoxyphenyl)sulfonyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 213183-83-6 CAPLUS

CN Propanamide, 3-[[4-(3,4-dimethylphenoxy)phenyl]sulfonyl]-N,2-dihydroxy-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 213183-84-7 CAPLUS

CN Propanamide, 3-[[4-(3,4-dimethylphenoxy)phenyl]sulfonyl]-N,2-dihydroxy-2-methyl- (9CI) (CA INDEX NAME)




RN 213183-85-8 CAPLUS

CN Propanamide, N,2-dihydroxy-2-(methoxymethyl)-3-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 213183-86-9 CAPLUS

CN 4-Morpholinepropanamide, .alpha.-[[[4-(3,4-dimethylphenoxy)phenyl]sulfonyl]methyl]-N,.alpha.-dihydroxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 213183-93-8 CAPLUS
 CN Propanamide, N,2-dihydroxy-2-(hydroxymethyl)-3-[[4-(phenylthio)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 213183-94-9 CAPLUS
 CN Benzamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]-4-pentyl- (9CI) (CA INDEX NAME)



RN 213183-96-1 CAPLUS
 CN Propanamide, N,2-dihydroxy-2-methyl-3-[[4-[(phenylamino)carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 213183-97-2 CAPLUS
 CN Benzamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 213183-98-3 CAPLUS

CN Butanamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 213183-99-4 CAPLUS

CN Benzamide, 4-chloro-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 213184-00-0 CAPLUS

CN Propanamide, N,2-dihydroxy-2-methyl-3-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 213184-01-1 CAPLUS

CN Propanamide, N,2-dihydroxy-2-methyl-3-[[4-[[[(3-methylphenyl)amino]carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 213184-03-3 CAPLUS

CN Propanamide, N,2-dihydroxy-2-methyl-3-[[4-[[[4-methylphenyl]amino]carbonyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 213184-04-4 CAPLUS

CN 3-Pyridinecarboxamide, 6-chloro-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 213184-06-6 CAPLUS

CN Benzamide, 4-(heptyloxy)-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 213184-07-7 CAPLUS

CN Benzamide, 4-butoxy-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 213184-08-8 CAPLUS

CN Benzamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]-4-propyl- (9CI) (CA INDEX NAME)




RN 213184-09-9 CAPLUS

CN Benzamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 213184-10-2 CAPLUS

CN Benzamide, 4-butyl-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 213184-12-4 CAPLUS

CN Benzamide, 3-fluoro-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 213184-13-5 CAPLUS

CN Benzamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 213184-14-6 CAPLUS

CN Benzamide, 3-chloro-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 213184-15-7 CAPLUS

CN Benzamide, 3,4-difluoro-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 213184-16-8 CAPLUS

CN Benzamide, N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 213184-17-9 CAPLUS

CN Benzamide, 3-[(4-hydroxybutyl)amino]-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 213184-18-0 CAPLUS

CN Benzamide, 3-amino-N-[4-[[2-hydroxy-3-(hydroxyamino)-2-methyl-3-oxopropyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:549278 CAPLUS

DOCUMENT NUMBER: 127:161589

TITLE: Preparation of substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds for inhibiting the prodn. or physiol. effects of TNF and cAMP phosphodiesterase.

INVENTOR(S): Groneberg, Robert D.; Neuenschwander, Kent W.; Djuric,

Stevan W.; Mcgeehan, Gerard M.; Burns, Christopher

J.;

Condon, Steven M.; Morrisette, Matthew M.; Salvino, Joseph M.; Scotese, Anthony C.; Ullrich, John W.; et al.

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA; Groneberg, Robert D.; Neuenschwander, Kent W.;

Djuric,

Stevan W.; Mcgeehan, Gerard M.; Burns, Christopher

J.;

Condon, Steven M.; Morrisette, Matthew M.

SOURCE: PCT Int. Appl., 251 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724117	A1	19970710	WO 1997-US264	19970102
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9715298	A1	19970728	AU 1997-15298	19970102
EP 871439	A1	19981021	EP 1997-901388	19970102
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2000503012	T2	20000314	JP 1997-524642	19970102
US 6057369	A	20000502	US 1997-928943	19970912
US 6133409	A	20001017	US 1998-103872	19980624
PRIORITY APPLN. INFO.:			US 1996-9484	P 19960102
			US 1996-32453	P 19961219
			US 1996-33881	P 19961224
			WO 1997-US264	W 19970102
			US 1997-928943	A2 19970912
			WO 1997-US23920	A2 19971217

OTHER SOURCE(S): MARPAT 127:161589

AB The title compds. HONHCOCpR1R2CR3R4[S(O)n]qCmR5R6Ar [I; R1 = H, optionally

substituted alkyl, alkenyl, or cycloalkyl, etc.; R2, R4-R6 = H, optionally

substituted alkyl, etc.; R3 = optionally substituted alkyl, alkenyl, cycloalkenyl, or cycloalkyl, etc.; Ar = (un)substituted aryl or heteriaryl; n = 0-2; m = 0-1; p = 0-1; q = 0-1] are prepd. I, possessing

tumor necrosis factor (TNF), matrix metalloproteinase (MMP), and cAMP phosphodiesterase inhibitory activity, are useful for prevention and treatment of a patient suffering from a disease state assocd. with a physiol. detrimental excess of tumor necrosis factor (TNF) and disease states including inflammatory and autoimmune diseases, etc. Thus, C₆H₅(CH₂)₄CH(SO₂C₆H₅)CH₂CO₂H (prepn. given) was treated with (COCl)₂ and then reacted with TMSONH₂ to give the title compd.
C₆H₅(CH₂)₄CH(SO₂C₆H₅)CH₂CONHOH.


IT **193547-69-2P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compds. for inhibiting the prodn. or physiol. effects of TNF and cAMP phosphodiesterase.)

RN 193547-69-2 CAPLUS

CN Benzeneheptanamide, N,.alpha.-dihydroxy-.beta.-[(4-methoxyphenyl)sulfonyl]-.alpha.-methyl- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 08:37:27 ON 09 MAY 2001)

FILE 'REGISTRY' ENTERED AT 08:37:49 ON 09 MAY 2001

L1 STRUCTURE UPLOADED
L2 QUE L1
L3 6 S L1
L4 STRUCTURE UPLOADED
L5 QUE L4
L6 6 S L4
L7 116 S L4 FUL


FILE 'CAPLUS' ENTERED AT 08:42:04 ON 09 MAY 2001

L8 5 S L7

=> d 14

L4 HAS NO ANSWERS

L4 STR



G1 Cy,Ak

G2 O,N,X

Structure attributes must be viewed using STN Express query preparation.

=> logoff